Percutaneous osteoplasty and interventions in VBCF – online course
Please note that this course is no longer CME accredited, but we are working on a new accredited version.
Authors: X. Buy, R. Cazzato and P. Lohle
Reviewers: F. Deschamps, M. Deutschmann, D. Filippiadis, G. Mauri and C. Nice
This course corresponds to chapters 188.8.131.52 Percutaneous Osteoplasty and 184.108.40.206.1 Interventions in Vertebral Body Compression Fractures (VBCF) in the European Curriculum and Syllabus for IR.
Percutaneous vertebroplasty is applied for the treatment of benign osteoporotic or malignant osteolytic vertebral body fractures. The procedure relies on poly(methyl methacrylate) (PMMA) injection inside the vertebral body in order to consolidate the fracture, achieve effective pain control and prevent further vertebral collapse. The aim of this course is to present the indications and contraindications of percutaneous vertebroplasty, and describe the technique and the devices that are commonly used.
- Learn the basics of percutaneous vertebral augmentation.
- Learn the indications and contraindications of percutaneous treatment in benign and malignant vertebral compression fractures (VCFs).
- Learn about the correct material needed for percutaneous vertebroplasty.
- Learn about the percutaneous vertebral approach at cervical, thoracic, lumbar and sacral levels.
- Learn how to avoid complications.
This course covers a basic level of IR knowledge and is designed for trainees, students or young consultants aiming to acquire essential knowledge or prepare for the EBIR exam. Thereby, it is tailored to the European Curriculum and Syllabus for IR and corresponds to chapters 220.127.116.11 Percutaneous Osteoplasty and 18.104.22.168.1 Interventions in Vertebral Body Compression Fractures (VBCF).
The format of the course is interactive and easy to use, including texts, graphics, videos and a quiz to support your learning. The course duration is around one hour.
Access to complete and revisit the course is granted for an enrolment period of 90 days.
Release date: March 2019